MSICS PHARMA LTD

Based in Tel Aviv, Israel, MSICS Pharma specializes in the development and production of innovative pharmaceutical applications utilizing naturally-sourced psilocybin to address various mental health conditions. MSICS Pharma is dedicated to creating pharmaceutical solutions from psilocybin, founded in 2020 and headquartered in Tel Aviv, Israel. Founded by brothers Roei Zerahia (CEO) and Omer Zerahia (CBO). MSICS Pharma focuses on developing and producing innovative pharmaceutical applications of naturally-sourced psilocybin, with its flagship product being MSX-06.

This product is designed to address significant mental health challenges including depression, obsessive-compulsive disorder (OCD), anxiety, and eating disorders. MSX-06 is currently in clinical trials in collaboration with various renowned hospitals, targeting patients who suffer from these medical conditions. The company is actively recruiting participants for these groundbreaking psilocybin-based trials, emphasizing their commitment to tackling unmet medical needs. MSICS Pharma's products are targeted at healthcare providers, research institutions, and pharmaceutical partners across multiple geographical markets, including North America and Europe, where the demand for advanced mental health therapies continues to grow.

The revenue model for MSICS Pharma is primarily structured around partnerships and collaborations with healthcare institutions and research organizations. The company engages in B2B transactions, particularly through clinical trial partnerships and product development agreements, which are crucial for validating the efficacy of its psilocybin product, MSX-06. These partnerships may encompass agreements where hospitals and research facilities receive funding or compensation in exchange for conducting clinical trials using MSX-06. While specific pricing plans for its products are not disclosed, the transaction structure suggests a focus on establishing strategic alliances that facilitate access to market-ready mental health solutions, enhancing the potential for revenue generation through successful product commercialization post-trials.

I n May 2026, MSICS Pharma raised USD 3. 6 million venture funding led by new investors Fusion, GlenRock Israel, SGL Acquisitions and Gooday Investment Ltd. Individual and other unspecified investors also participated in the round. The company will use the May 2026 funding to expand production, accelerate clinical trials, and prepare its psilocybin-based product for global markets.